Kiora Pharmaceuticals, Inc. announced that effective as of June 16, 2022, Drexler resigned as Interim Chief Financial Officer of the Company, but will continue to provide consulting services to the Company pursuant to the Consulting Agreement. Drexler's resignation did not result from any disagreement regarding the Company's operations, policies or practices. In connection with Drexler's resignation, Brian M. Strem, Ph.D., the Company's President and Chief Executive Officer, will assume the role of the Company's principal financial and accounting officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5328 USD | -1.33% | +3.46% | +1.99% |
05-10 | Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M | MT |
03-25 | Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.99% | 14.18M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- KPRX Stock
- News Kiora Pharmaceuticals, Inc.
- Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer